Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Optimal Timing of Hepatitis B Vaccination After Transplants

Phase 3

Not yet recruiting

Conditions: Transplant-Related Disorder
Hepatitis B Virus Infection
Vaccine Reaction

Interventions: Biological: hepatitis B vaccine

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 1500

Registration Number: NCT06888479

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients

Phase 1

Not yet recruiting

Conditions: HIV Infected Individuals
HIV

Interventions: Biological: HIV-CAR-T

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3

Registration Number: NCT06880380

Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

Phase 2

Not yet recruiting

Conditions: Acute Graft-versus-Host Disease

Interventions: Drug: Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 174

Registration Number: NCT06880419

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Biological: anti-BCMA-CAR-T

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 40

Registration Number: NCT06880393

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: CLL1 and CD38 Dual-Target CAR-T Cell Injection

First Posted Date: 2025-03-17

Last Posted Date: 2025-06-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 37

Registration Number: NCT06880354

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, TianJin, China

Newly-diagnosed Pediatric T-cell ALL Protocol

Phase 2

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia
Childhood Leukemia, Acute Lymphoblastic
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Interventions: Drug: Venetoclax
Drug: Dasatinib
Drug: homoharringtonine

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 610

Registration Number: NCT06855810

Locations: 🇨🇳
Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
🇨🇳
Anhui Provincial Children's Hospital, Hefei, Anhui, China
🇨🇳
Chongqing Medical University Affiliated Children's Hospital, Chongqing, Chongqing, China

and more 23 locations

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

Phase 2

Recruiting

Conditions: Herombopag

Interventions: Drug: herombopag olamine tablets

First Posted Date: 2025-02-21

Last Posted Date: 2025-03-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 80

Registration Number: NCT06838949

Locations: 🇨🇳
Chinese academy of medical science and blood disease hospital, Tianjin, China

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia (ITP)
Treatment

Interventions: Drug: CM336 Injection

First Posted Date: 2025-01-29

Last Posted Date: 2025-03-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06799611

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Poor Graft Function

Interventions: Biological: Dose escalation
Biological: Dose extension

First Posted Date: 2025-01-27

Last Posted Date: 2025-03-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 15

Registration Number: NCT06792682

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin, China

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Biological: ASCT
Biological: anti-BCMA CAR-T

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 80

Registration Number: NCT06793449

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy